S P Langdon
Overview
Explore the profile of S P Langdon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1098
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gray M, Meehan J, Ward C, Langdon S, Kunkler I, Murray A, et al.
Vet J
. 2018 Sep;
239:21-29.
PMID: 30197105
Precision medicine can be defined as the prevention, investigation and treatment of diseases taking individual variability into account. There are multiple ways in which the field of precision medicine may...
2.
Koussounadis A, Langdon S, Harrison D, Smith V
Br J Cancer
. 2014 May;
110(12):2975-84.
PMID: 24867692
Background: The response of ovarian cancer patients to carboplatin and paclitaxel is variable, necessitating identification of biomarkers that can reliably predict drug sensitivity and resistance. In this study, we sought...
3.
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
Sims A, Zweemer A, Nagumo Y, Faratian D, Muir M, Dodds M, et al.
Br J Cancer
. 2012 May;
106(11):1779-89.
PMID: 22549178
Background: Trastuzumab and pertuzumab target the Human Epidermal growth factor Receptor 2 (HER2). Combination therapy has been shown to provide enhanced antitumour activity; however, the downstream signalling to explain how...
4.
Bartlett J, Rabiasz G, Scott W, Langdon S, Hirst G, Lee A, et al.
Oncol Rep
. 2011 May;
2(5):857-62.
PMID: 21597831
The role of the insulin-like growth factors (IGFs) in 3 cultured human ovarian cancer cell lines (PEO1, PEO4, PEO14) was investigated. All three cell lines express mRNA for IGF-I and...
5.
Mullen P, Langdon S
Methods Mol Med
. 2011 Feb;
39:199-203.
PMID: 21340773
The fact that human tumor xenografts grown in immunodeficient mice have proven to be useful models of human cancer is well documented. However, the establishment of such xenografts from cell...
6.
Ritchie A, Langdon S
Methods Mol Med
. 2011 Feb;
39:193-8.
PMID: 21340772
The use of human tumor xenografts grown in immunodeficient animals as a model for human cancers is well established and their value depends on the extent to which their characteristics...
7.
Langdon S, Lawrie S
Methods Mol Med
. 2011 Feb;
39:155-9.
PMID: 21340766
Human tumor cell lines have provided valuable model systems to study a wide variety of tumor characteristics including the cell biology, genetics, and chemosensitivity profiles of disease. A large number...
8.
Langdon S, Edwards J, Bartlett J
Methods Mol Med
. 2011 Feb;
39:145-53.
PMID: 21340765
Perhaps the most fundamental question that faces the laboratory scientist is, "Which model system should I use to investigate the problem?" Failure to adequately address this issue can compromise even...
9.
Katz E, Dubois-Marshall S, Sims A, Faratian D, Li J, Smith E, et al.
Br J Cancer
. 2010 Jul;
103(3):401-10.
PMID: 20628393
Background: C35 is a 12 kDa membrane-anchored protein endogenously over-expressed in many invasive breast cancers. C35 (C17orf37) is located on the HER2 amplicon, between HER2 and GRB7. The function of...
10.
Faratian D, Aitken S, Thomas J, Langdon S, Harrison D
Ann Oncol
. 2010 Mar;
21(6):1375.
PMID: 20215137
No abstract available.